20,000 Shares in Urogen Pharma $URGN Acquired by JW Asset Management LLC

JW Asset Management LLC purchased a new stake in Urogen Pharma (NASDAQ:URGN) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 20,000 shares of the company’s stock, valued at approximately $813,000. Urogen Pharma accounts for about 0.3% of JW Asset Management LLC’s investment portfolio, making the stock its 19th biggest holding.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Russell Investments Group Ltd. boosted its holdings in shares of Urogen Pharma by 92.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 183,076 shares of the company’s stock worth $7,438,000 after buying an additional 88,097 shares during the period. CenterBook Partners LP acquired a new position in Urogen Pharma in the 3rd quarter valued at $642,000. Calamos Advisors LLC acquired a new position in Urogen Pharma in the 3rd quarter valued at $246,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Urogen Pharma in the 3rd quarter worth $101,000. Finally, State of Wyoming raised its holdings in Urogen Pharma by 773.4% in the 3rd quarter. State of Wyoming now owns 4,629 shares of the company’s stock worth $188,000 after acquiring an additional 4,099 shares during the period. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Urogen Pharma Price Performance

URGN opened at $26.39 on Friday. Urogen Pharma has a 1-year low of $16.50 and a 1-year high of $50.81. The business has a 50 day moving average of $37.38 and a 200-day moving average of $31.65.

Urogen Pharma (NASDAQ:URGN) last released its earnings results on Wednesday, November 4th. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of $0.11 by ($0.14). The company had revenue of $89.00 million for the quarter, compared to analysts’ expectations of $89.92 million. Equities research analysts predict that Urogen Pharma will post -0.36 earnings per share for the current fiscal year.

Insider Activity

In related news, General Counsel Jason Smith sold 1,519 shares of the stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $42.54, for a total value of $64,618.26. Following the completion of the sale, the general counsel owned 53,141 shares in the company, valued at approximately $2,260,618.14. This trade represents a 2.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Chris Degnan sold 2,202 shares of the stock in a transaction dated Thursday, October 8th. The shares were sold at an average price of $36.69, for a total transaction of $80,791.38. Following the completion of the sale, the chief financial officer owned 4,561 shares of the company’s stock, valued at approximately $167,343.09. The trade was a 32.56% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 65,269 shares of company stock valued at $3,037,646. Insiders own 4.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Oppenheimer set a $60.00 target price on shares of Urogen Pharma in a research report on Thursday, November 5th. TD Cowen upped their price target on shares of Urogen Pharma from $50.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Guggenheim lowered their price target on Urogen Pharma from $58.00 to $56.00 and set a “buy” rating on the stock in a research report on Thursday, November 5th. UBS Group reiterated an “outperform” rating on shares of Urogen Pharma in a research note on Thursday, November 5th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $56.00 price objective on shares of Urogen Pharma in a research report on Thursday, September 10th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $53.38.

About Urogen Pharma

UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. Its work centers on therapies delivered directly to the urinary system, including treatments for certain forms of urothelial cancer. The company’s products include Jelmyto, a mitomycin-based treatment delivered to the upper urinary tract for adults with low-grade upper tract urothelial cancer, and Zusduri, a mitomycin-based treatment for adults with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer.